Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

Hands

The release of the long-awaited outcomes trial for Sanofi/Regeneron Pharmaceuticals Inc.'s PCSK9 inhibitor at the American College of Cardiology Scientific Sessions was a big news event for the cholesterol-lowering field, but the announcement that the firms will lower the price of Praluent (alirocumab) in the US in line with a recommendation from the Institute for Clinical and Economic Review (ICER) stands out for the potential to set a precedent for the pharmaceutical industry. 

The two drug partners announced March 10 they would lower the price of Praluent to a level ICER deemed cost...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access